Pharma News

Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide, yet the majority of these patients are excluded from the early stages in the development of new, anti-tuberculosis drugs, according to findings presented today (29 September, 2015) at the European Respiratory Society's International Congress 2015.

Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck’s comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.1

Updated results from the CheckMate 057 phase III clinical trial, show that nivolumab continues to show an overall survival benefit compared to docetaxel in patients with non-squamous non-small cell lung cancer

Tooth enamel is the hardest substance produced by our body, composed almost entirely of the mineral apatite (calcium phosphate) deposited on a substrate of three unique enamel matrix proteins. New research suggests that tooth enamel originated in the skin. Researchers from Uppsala University in Sweden and the Institute of Vertebrate Paleontology and Paleoanthropology (IVPP) in China combined data from paleontology and genomics to arrive at the answer. The study appeared in the journal Nature.

Researchers at The Scripps Research Institute (TSRI), Florida in the US have identified a new class of compounds with the potential to stop 'chronic intractable itch' without the adverse side effects. The study was published in the journal Neuropharmacology.

[adsense:336x280:8701650588]

The Medical Research Council researchers analyzed huge amount amount of health and genetic data from volunteers to the UK's Biobank project. The analysis of more than 50,000 people showed favorable mutations in people's DNA-enhanced lung function and masked the deadly impact of smoking.

- Company increases its investments in India across R&D, manufacturing, people and community programs
- Abbott invests in New Mumbai corporate office in the Bandra Kurla complex

• Interim analysis of INPULSIS®-ON study shows: Beneficial effect of OFEV®* on slowing disease progression was maintained and the change from baseline in FVC was consistent over 2 years
  
• Long-term treatment with OFEV®* had a manageable safety and tolerability profile (mean exposure of 2.4 years, maximum exposure of more than 3 years)
  
• Commonly used concomitant medications, such as anti-acids or systemic steroids, do not influence the beneficial effect of OFEV®* on slowing disease progression
  

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

A new study suggests that the survival rate of premature babies born between 26 to 31 weeks of gestation can be improved by blocking light from reaching the intravenously-fed infused nutritious mixture for survival. The study was published in the Journal of Parenteral and Enteral Nutrition.